Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
1998

Cost-effectiveness of Erythropoietin for Chemotherapy-Induced Anaemia

Sample size: 125 publication Evidence: low

Author Information

Author(s): G Barosi, M Marchetti, NL Liberato

Primary Institution: IRCCS Policlinico S. Matteo, Pavia, Italy

Hypothesis

Is recombinant human erythropoietin (rHuEPO) cost-effective compared to conventional treatment for chemotherapy-induced anaemia?

Conclusion

Recombinant human erythropoietin is not cost-effective for treating chemotherapy-induced anaemia under current usage patterns.

Supporting Evidence

  • rHuEPO increased quality-adjusted life expectancy by 8.4 days.
  • The incremental cost-effectiveness of rHuEPO was $189,652 per QALY.
  • Transfusion therapy alone remained the most cost-effective strategy.
  • Even with favorable assumptions, rHuEPO's cost-effectiveness remained high.
  • At current prices, rHuEPO is not cost-effective for chemotherapy-induced anaemia.

Takeaway

This study looked at whether a drug called erythropoietin, which helps with anaemia during cancer treatment, is worth the money compared to just using blood transfusions. It found that using the drug costs too much for the benefits it provides.

Methodology

Decision analysis comparing rHuEPO with RBC transfusions alone.

Potential Biases

Potential bias in favor of rHuEPO due to assumptions made in the analysis.

Limitations

The analysis is based on a hypothetical patient model and may not reflect real-world variability.

Participant Demographics

Mean age of 65 years, patients with severe anaemia due to chemotherapy.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication